Screener / SEC EDGAR /CIK 0001628171 /10-K filed Feb 25, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Revolution Medicines, Inc. RVMD

Compare with peers Embed
SEC comment letters, last 20 years

2 reviews of RVMD's filings by SEC staff

UPLOAD and CORRESP
Reviews 2 latest letter Apr 9, 2024
Questions asked 21 each answered in the company's own letter
No closing letter 1 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 5 UPLOAD
  2. 2. Questions in them 21 numbered comments
  3. 3. Company replies 8 CORRESP
  4. 4. Reviews closed 1 of 2 closing letter

Half the closed reviews took 17 days or less from the first letter to the closing letter.

Form 10-K

2024-04-09 to 2024-04-26 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2024-04-26
Results discussion (MD&A)
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations · Research and development expenses, page 91
SEC asked
We note from the pipeline table on page 9 that you have multiple products that are in clinical development. Please revise future filings to disclose the costs incurred during each period presented for each of your key research and development product candidates.
Rest of the question

If you do not track your research and development costs by project, disclose that fact and explain why you do not maintain and evaluate research and development costs by project. Also, revise to provide other quantitative and qualitative disclosures that give more transparency as to the type of research and development expenses incurred (i.e., by nature or type of expense) which should reconcile to total research and development expenses on your Statements of Operations.

RVMD answered
Company’s Response: The Company respectfully acknowledges the Staff’s comment and advises the Staff that the Company, in future filings, commencing with its Quarterly Report on Form 10-Q for the period ended March 31, 2024, will provide the requested disclosure relating to costs incurred for the Company’s key research and development product candidates, including quantitative and qualitative disclosures as to the type of research and development expenses, for each period presented.

We hope that the foregoing has been responsive to the Staff’s comment.
Rest of the answer

Please do not hesitate to contact me by telephone at (650) 463-3043 or by email at [email protected] with any questions or comments regarding this correspondence.

Read in the reply
In its next report

First report after the company's reply of Apr 19, 2024: 10-Q filed May 8, 2024 ↗, against the 10-Q filed Nov 6, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2024-04-26

Form S-1

2019-10-16 to 2020-07-06 · 20 questions · 4 letters from the SEC, 7 from the company
No closing letter
Results discussion (MD&A)Legal and contingenciesCritical estimatesAcquisitionsRevenueExecutive pay
Prospectus Summary · Overview, page 1
SEC asked (1)
Please revise here and throughout to avoid conclusory statements regarding your product candidates and the results of your clinical tests and preclinical studies by describing how you conducted the tests, the number of tests conducted and the range of results observed.
Rest of the question

For example, we note your disclosure on page 1 that RMC-4630 is a "potent and selective inhibitor of SHP2," your statement on page 4 regarding your "ability to inhibit various oncogenic RAS(ON) mutants" and your statement on page 108 that you have "substantial preclinical evidence that SHP2 is a central node that can be targeted to disrupt signaling pathways that may involve activation of multiple RTKs."

RVMD answered
Medicines, Inc. (the “Company”), set forth below is information in response to comment number 9 contained in the letter to the Company dated October 16, 2019 from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) relating to the Draft Registration Statement on Form S-1 that was originally confidentially submitted to the Commission on September 19, 2019 and, as subsequently revised, was publicly filed by the Company on January 17, 2020 (the “Registration Statement”).
Rest of the letter

The supplemental response set forth below is based upon information provided to On behalf of the Company, we are respectfully requesting confidential treatment for specified portions of this letter pursuant to Rule 83 promulgated by the Commission (17 C.F.R. § 200.83). This letter is accompanied by such request for confidential treatment because of the commercially sensitive nature of the information discussed in this letter. A redacted version of this letter will be filed with the Commission on EDGAR, omitting the confidential information. The Company’s discussion of its accounting for stock-based compensation is primarily contained within the sections of the Registration Statement entitled “Management’s discussion and analysis of financial condition and results of operations—Critical accounting policies, significant judgments and use of estimates—Stock-based compensation” and “—Common stock valuation” (the “MD&A”) and appears on pages 105 through 106 of the Registration Statement. The Company confirms to the Staff that no price range has yet been provided in the preliminary prospectus included in the Registration Statement. However, the Company has authorized us to inform the Staff supplementally that, based on consultations with the lead underwriters, input received from testing-the-waters meetings (the “TTW Meetings”), and considerations of the current market conditions, if the marketing of the initial public offering (the “IPO”) were to commence today, the Company’s present view is that the estimated offering range would be $[***] to $[***] per share (the “Preliminary IPO Price Range”). The share numbers, Preliminary IPO Price Range, exercise prices and fair values do not take into account a reverse stock split that the Company intends to implement in connection with the IPO. The Company advises the Staff that the Preliminary IPO Price Range represents the Company’s current belief of what the indicative price range in the preliminary prospectus may be, but that the actual indicative price range in the preliminary prospectus will not be determined until the Company completes a valuation process with the underwriters of the IPO, which is expected to occur shortly before the printing of the preliminary prospectus for the IPO. Therefore, the preliminary estimated indicative price range is subject to further change as a result of various factors, including market conditions and subsequent developments with respect to the Company’s business. Upon completion of this valuation process, the Company will narrow the indicative price range to establish a bona fide offering price range not to be greater than $[***] between the low end of the range and the top end of the range. To assist the Staff in its evaluation of the Company’s accounting for stock-based compensation, the Company has provided the analysis as set forth below. DETERMINATION OF FAIR VALUE OF COMMON STOCK As described in the Registration Statement, the Company has historically determined the fair value of its common stock using methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation (the “Practice Guide”). Specifically, the fair value of the shares of common stock underlying the Company’s stock options has been determined by the Company’s Board of Directors (the “Board”). Because there has been no public market for the Company’s common stock, and in the absence of recent arm’s-length cash sales transactions of the Company’s common stock with independent third parties, the Board has determined the fair value of the common stock by considering a number of objective and subjective factors, including independent third-party valuations as of December 31, 2018, May 31, 2019 and September 30, 2019. The Board gave consideration to expected material grants of common stock options in determining when to obtain independent third-party valuations. As described in greater detail in the MD&A, these valuations have utilized combinations of (i) the income approach (in the particular, the discounted cash flow (“DCF”) analysis), (ii) the option-pricing method (“OPM”) and (iii) the probability-weighted expected return method (“PWERM”) for determining the fair value of the Company’s common stock. A DCF analysis attempts to value an asset or security by estimating the present value of the future cash flows it is expected to produce. Projected cash flows are then discounted to a present value employing a discount rate that properly accounts for the estimated market-weighted average cost of capital, as well as any risk unique to the subject cash flows. The OPM uses option theory to value the various classes of a company’s securities in light of their respective claims to the company’s total stockholders’ equity. In particular, total stockholders’ equity value is allocated to the various share classes based upon their respective claims on a series of call options with strike prices at various value levels depending upon the rights and preferences of each class of equity. Under the PWERM, the per share value of the common stock is estimated based upon the probability-weighted present value of expected future equity values for the common stock, under various possible future liquidity event scenarios, in light of the rights and preferences of each class of equity, discounted for a lack of marketability. For the valuations conducted prior to September 30, 2019, the Company utilized a DCF analysis to estimate the fair value of the Company’s total stockholders’ equity, and then utilized the OPM to allocate such value to the various classes of the Company’s equity, as described in further detail below. Beginning with the September 30, 2019 Valuation (as defined below), the Company utilized a hybrid approach of the OPM and the PWERM, an accepted valuation approach under the Practice Guide, for determining the fair value of the Company’s common stock (the “Hybrid Method”). The Hybrid Method estimates the probability-weighted value across multiple scenarios but uses the OPM to estimate the allocation of value within one or more of the scenarios. The Company determined to incorporate the PWERM into its valuation methodology as values associated with various potential outcomes were considered estimable, in light of the Company’s stage of development, operating results, its prospects for an IPO in the near term, general conditions in the capital markets, including with respect to IPOs, and the relative likelihood of achieving a liquidity event such as an IPO in light of prevailing market conditions. At each grant date, the Board evaluated any recent events and their potential impact on the estimated fair value per share of the common stock. For grants of stock awards made on dates for which there was no concurrent independent third-party valuation, the Board determined the fair value of the common stock on the date of grant taking into consideration the immediately preceding valuation report as well as other pertinent information available at the time of the grant. In the course of preparing the Company’s consolidated financial statements with a retrospective view, the Company also estimated the fair value of its common stock for financial reporting purposes. For purposes of this determination with respect to the Company’s stock option grants after May 31, 2019, the Company assumed that the fair value of the common stock increased on a linear basis from the valuation preceding the applicable grants to the valuation RVMD-1003 following the applicable grants (or, in the case of the grants made on December 18, 2019, the midpoint of the Preliminary IPO Prince Range of approximately $[***] per share (the “Midpoint Price”)). The Company believes that a linear interpolation is appropriate as no single event caused the valuation of the Company’s common stock to fluctuate. Instead, a combination of Company-specific factors, including its progress toward an IPO, more certainty around the Company’s business and financial position as well as external market factors, led to the changes in the fair value of the underlying common stock. Applying this linear interpolation, the Company determined the fair value of its common stock for financial reporting purposes. The following table summarizes by grant date the number of shares of common stock underlying stock options granted during the previous 12 months, as well as the associated per share exercise price and the estimated fair value per share of the Company’s common stock on the grant date for financial reporting purposes. Fair Value per Share for Financial Reporting See Note 1 on page 6 below for a discussion regarding the difference between the exercise price per share and estimated grant-date fair value for financial reporting purposes. Fair value determined for financial reporting purposes, assuming that the fair value of the Company’s common stock increased on a linear basis from the fair value of its common stock as determined pursuant to the May 31, 2019 Valuation (as defined below), which was $0.92 per share, to the fair value of its common stock as determined pursuant to the September 30, 2019 Valuation, which was $1.54 per share. common stock increased on a linear basis from the fair value of its common stock as determined pursuant to the September 30, 2019 Valuation, which was $1.54 per share, to the Midpoint Price. VALUATIONS AND OPTION GRANTS OVER THE PREVIOUS 12 MONTHS December 31, 2018 Valuation and March 13, 2019 Grants A valuation was performed by the Company with the assistance of a third-party independent valuation specialist that determined the fair value of the Company’s common stock as of December 31, 2018 to be $0.84 per share (the “December 31, 2018 Valuation”). For the December 31, 2018 Valuation, the Company utilized a DCF analysis to estimate the value of the Company’s total stockholders’ equity as $[***] million on a minority, marketable basis. The Company then employed the OPM to allocate the total stockholders’ equity value to the various classes of the Company’s stockholders based on their respective claims on a series of call options with strike prices at various value levels depending on the rights and preferences of each RVMD-1004 class. The Company did not utilize the PWERM in the December 31, 2018 Valuation because the Company had not, at the time of such valuation, initiated discussions with bankers or begun planning regarding a potential IPO, and therefore could not, at such time, reasonably estimate the form and timing of potential liquidity events. In applying the OPM, the Company utilized an estimated time to liquidity of [***] years, a risk free rate of [***]% and an estimated volatility of [***]%, which resulted in an estimated fair value of the Company’s common stock of $[***] per share, on a minority, marketable basis. In determining the estimated fair value of the common stock, the Board and the third-party valuation firm also considered the fact that the Company’s stockholders could not freely trade the common stock in the public markets. Because the common stock represented a non-marketable equity interest in a private enterprise, a discount for lack of marketability (“DLOM”) of [***]% was applied to the estimated fair value of the common stock on a marketable basis, resulting in an estimated fair value of the common stock of $0.84 per share on a minority, non-marketable basis. The DLOM was estimated based on consideration of both a simple protective put analysis, as well as the modified put analysis known as the Finnerty Method, a method of estimating a DLOM using the OPM as outlined in the Practice Guide. In connection with the grants of stock options made on March 13, 2019, the Board concluded that the estimated fair value of the Company’s common stock was $0.84 per share in consideration of the valuation analysis as of December 31, 2018 and other objective and subjective factors as appropriate. For financial reporting purposes, no interpolation was performed because there was not a significant increase in the fair value of common stock between the valuations preceding and following these option grants. May 31, 2019 Valuation and August 9, 2019 and September 11, 2019 Grants A valuation was performed by the Company with the assistance of a third-party independent valuation specialist that determined the fair value of the Company’s common stock as of May 31, 2019 to be $0.92 per share (the “May 31, 2019 Valuation”). For the May 31, 2019 Valuation, the Company utilized a DCF analysis to estimate the value of the Company’s total stockholders’ equity as $[***] million on a minority, marketable basis. The Company then employed a multi-scenario OPM analysis to compute the probability-weighted value of the common stock across two scenarios: the IPO and the non-IPO scenarios. The Company included an IPO scenario in light of the Company’s stage of development, operating results, its prospects for an IPO in the near term following the organizational meeting for its IPO on July 30, 2019, general conditions in the capital markets, including with respect to IPOs, and the relative likelihood of achieving a liquidity event such as an IPO in light of prevailing market conditions. Based on these considerations, the Company assigned a [***]% probability to the IPO scenario and a [***]% probability to the non-IPO scenario. In applying the OPM for the IPO scenario, the Company utilized an estimated time to liquidity of [***] years, a risk free rate of [***]% and an estimated volatility of [***]%, which resulted in an estimated fair value of the common stock in the IPO scenario of $[***] per share, on a minority, marketable basis. In applying the OPM for the non-IPO scenario, the Company RVMD-1005 utilized an estimated time to liquidity of [***] years, a risk free rate of [***]% and an estimated volatility of [***]%, which resulted in an estimated fair value of the common stock in the non-IPO scenario of $[***] per share, on a minority, marketable basis. Because the common stock represented a non-marketable equity interest in a private enterprise, a DLOM of [***]% was applied in the IPO scenario and a DLOM of [***]% was applied in the non-IPO scenario, resulting in estimated fair values of the common stock of $[***] per share and $[***] per share, respectively. The DLOMs were estimated based on consideration of both a simple protective put analysis, as well as the Finnerty Method. Applying the estimated probabilities of [***]% to the IPO scenario and [***]% to the non-IPO scenario, the Company estimated that the fair value of common stock as of May 31, 2019 was $0.92 per share on a minority, non-marketable basis. The following table sets forth the results of the multi-scenario OPM analysis used to determine the estimated value per share of the Company’s common stock in the May 31, 2019 Valuation: Estimated fair value of common stock on a minority, marketable basis Estimated fair value per share on a minority, non-marketable basis Probability-weighted fair value per share In connection with the grants of stock options made on August 9, 2019 and September 11, 2019, the Board concluded that the estimated fair value of the Company’s common stock was $0.97 per share in consideration of the valuation analysis as of May 31, 2019 and other objective and subjective factors as appropriate.1 For financial reporting purposes, linear interpolation was used to calculate the grant date fair value for these grants based on the May 31, 2019 Valuation and the September 30, 2019 Valuation (as defined below). The Company believes that a linear interpolation is appropriate as no single event caused the valuation of the Company’s common stock to fluctuate. Instead, a combination of Company-specific factors, including its progress toward an IPO, more certainty around the Company’s business and financial position as well as external market factors, led to the changes in the fair value of the underlying common stock. Applying this linear interpolation, the Company determined the grant date fair value of its common stock for financial reporting purposes for the August 9, 2019 grants was $1.28 per share and for the September 11, 2019 grant was $1.44 per share. In connection with the preparation of the Company’s consolidated financial statements, the Company, in consultation with the third-party independent valuation specialist, subsequently determined that the fair value of the Company’s common stock as of May 31, 2019 should have been calculated as $0.92 per share based on the third-party valuation specialist’s original valuation analysis. While the exercise price of stock option grants made in August and September 2019 was $0.97 per share, the Company has reported the grant date fair value of such grants, after taking into account the linear interpolation described herein, based on the revised calculation of $0.92 per share. September 30, 2019 Valuation and December 18, 2019 Grants A valuation was performed by the Company with the assistance of a third-party independent valuation specialist that determined the fair value of the Company’s common stock as of September 30, 2019 to be $1.54 per share (the “September 30, 2019 Valuation” and, together with the December 31, 2018 Valuation and the May 31, 2019 Valuation, each, a “Valuation”). For the September 30, 2019 Valuation, the Company employed the Hybrid Method to compute the probability-weighted value of the common stock across two scenarios: the IPO and the non-IPO scenarios. In the IPO scenario, the Company utilized valuation data reviewed in IPO discussions, taking into account subsequent market trends, to estimate the Company’s pre-IPO valuation of $[***] million (assuming the completion of the IPO in the first quarter of 2020), which was then discounted to $[***] million, as of the valuation date, utilizing a [***]% market weighted-average cost of capital. In the non-IPO scenario, the Company utilized a DCF analysis to estimate the value of the Company’s total stockholders’ equity as $[***] million on a minority, marketable basis. The Company assigned a [***]% probability to the IPO scenario and a [***]% probability to the non-IPO scenario. As of the valuation date, the Company considered the following factors in the aggregate in increasing the probability for the IPO scenario by [***]%, compared to the May 31, 2019 The Company confidentially submitted a draft registration statement to the Commission on September 19, 2019; The Company dosed its first patient in its Phase 1b/2 clinical trial of RMC-4630 in combination with cobimetinib in September 2019. In applying the OPM for the IPO scenario, the Company utilized an estimated time to liquidity of [***] years, a risk free rate of [***]% and an estimated volatility of [***]%, which resulted in an estimated fair value of the common stock in the IPO scenario of $[***] per share, on a minority, marketable basis. In applying the OPM for the non-IPO scenario, the Company utilized an estimated time to liquidity of [***] years, a risk free rate of [***]% and an estimated volatility of [***]%, which resulted in an estimated fair value of the common stock in the non-IPO scenario of $[***] per share, on a minority, marketable basis. A DLOM of [***]% was applied in the IPO scenario and a DLOM of [***]% was applied in the non-IPO scenario, resulting in estimated fair values of the common stock of $[***] per share and $[***] per share, respectively. The DLOMs were estimated based on consideration of both a simple protective put analysis, as well as the Finnerty Method. Compared to the May 31, 2019 Valuation, the Company applied a lower DLOM in the IPO scenario considering the compressed term to exit. Applying the estimated probabilities of [***]% to the IPO scenario and [***]% to the non-IPO scenario, the Company estimated that the fair value of common stock as of September 30, 2019 was $1.54 per share on a minority, non-marketable basis. The following table sets forth the results of the Hybrid Method analysis used to determine the estimated value per share of the Company’s common stock in the September 30, 2019 Valuation: In connection with the grants of stock options made on December 18, 2019, the Board concluded that the estimated fair value of the Company’s common stock was $1.54 per share in consideration of the valuation analysis as of September 30, 2019 and other objective and subjective factors as appropriate. For financial reporting purposes, linear interpolation was used to calculate the grant date fair value for these grants based on the September 30, 2019 Valuation and the Midpoint Price. The Company believes that a linear interpolation is appropriate as no single event caused the valuation of the Company’s common stock to fluctuate. Instead, a combination of Company-specific factors led to the changes in the fair value of the underlying common stock, including the following factors: Continued progress towards an IPO, including that the Company had confidentially submitted a revised draft registration statement to the Commission on October 31, 2019 and had engaged in initial TTW Meetings; and More certainty around the Company’s business and financial position, including that in November 2019, the Company entered into a clinical trial collaboration agreement with Amgen, Inc. to evaluate RMC-4630 in combination with AMG 510, and that in November 2019, the Company received preliminary data from the Company’s Phase 1 clinical program of RMC-4630. Company has made a determination that the grant date fair value of its common stock for financial reporting purposes for the December 18, 2019 grants was $[***] per share. DISCUSSION OF PRELIMINARY IPO PRICE RANGE The Preliminary IPO Price Range was derived by a quantitative and qualitative analysis that differed from the methodology used by the Company and its independent valuation specialist. Among the factors that were considered in setting the Preliminary IPO Price Range were the following: an analysis of the typical valuation ranges seen in recent IPOs for comparable companies in the Company’s industry; the general condition of the securities markets and the recent market prices of publicly traded common stock of comparable companies; an assumption that there would be a receptive public trading market for biotechnology companies such as the Company; and an assumption that there would be sufficient demand for the Company’s common stock to support an offering of the size contemplated by the Company. The Company respectfully submits that the difference between the Midpoint Price and the fair value of the Company’s common stock as determined by the September 30, 2019 Valuation, is primarily attributable to the fact that the methodology in the September 30, 2019 Valuation incorporated multiple probability-weighted scenarios, not all of which allocate value to the Company’s common stockholders, and inherently decreases the estimated fair value per share due to the combination of (i) the mix of other expected business equity values discounted for their future value and (ii) the application of a discount to account for lack of marketability. In contrast, the Midpoint Price assumes with 100% probability that the Company completes an IPO and the Company’s preferred stock will be converted into common stock during the first quarter of 2020. Additionally, the Midpoint Price assumes only a single potential liquidity event, the IPO, and does not include a DLOM, as an active trading market for the common stock is expected to exist following the IPO. As a result, the Midpoint Price was not impacted by other expected business equity values from other potential future liquidity events nor discounted for lack of marketability. The Company believes that the remaining difference between the Midpoint Price and fair value of the Company’s common stock as determined by the September 30, 2019 Valuation is attributable to the fact that the valuation report prepared by the Company’s third-party valuation specialist utilized a quantitative methodology to determine the fair value of the Company’s common stock, which may differ from the more qualitative and subjective methodology used by some public market investors to determine the price that they are willing to pay in the IPO, such as the valuations of recently completed public offerings and the evaluations of those issuers’ respective stages of development as compared to the Company, the current valuations of public companies at a similar stage of clinical development, and recent market conditions. Also, other factors may have an impact, such as the inherent uncertainty of completing an IPO and the possibility that the actual offering price could be substantially lower than the estimated offering price range determined by the Company and the lead underwriters. Preliminary IPO Price Range and the other factors described in this letter, the Company respectfully advises the Staff that it believes that the deemed per share fair values of the Company’s common stock RVMD-1009 used as the basis for determining stock-based compensation expense in connection with its stock option grants have been reasonable and appropriate. Should the Staff have any questions or comments regarding the Registration Statement or this letter, please contact me by telephone at (650) 463-3043 or by e-mail at [email protected].

One letter for all the questions, without numbered answers. Read the reply
Prospectus Summary · Overview, page 1
SEC asked (2)
We note your disclosure on page 1 and throughout regarding your "deep" pipeline and your "deep differentiated pipeline." Please balance this disclosure here and throughout by disclosing that you have only one product candidate that is in clinical testing and that all of your other potential product candidates are in the preclinical and development stage.
Rest of the question

Similarly, please balance your disclosure on page 3 that you believe that RMC-4630 is well positioned to become the backbone of targeted therapy combinations for the treatment of various RAS-dependent tumors and your disclosure on page 109, which describes how each category of your product candidates acts to inhibit cancer cells, by addressing your early stage of clinical testing, preclinical studies and the development of product candidates.

RVMD answered

See the reply above.

Prospectus Summary · Overview, page 1
SEC asked (3)
Please revise your pipeline chart to include a column for each clinical stage. In this regard, we note that you have combined Phases 1 and 2 into a single column.
RVMD answered

See the reply above.

Prospectus Summary · Overview, page 1
SEC asked (4)
Please revise to include a brief definition here of what you mean by "frontier cancer targets."
RVMD answered

See the reply above.

Implications of being an emerging growth company, page 6
SEC asked (5)
Please provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications.
RVMD answered

See the reply above.

Risks related to our common stock and this offering · Our amended and restated certificate of incorporation will provide for an exclusive forum, page
SEC asked (6)
We note that your forum selection provision identifies the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation, including any “proceeding brought on [y]our behalf.” Please disclose whether this provision applies to actions arising under the Securities Act or Exchange Act.
Rest of the question

In that regard, we note that Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder, and Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. If the provision applies to Securities Act claims, please also revise your prospectus to state that there is uncertainty as to whether a court would enforce such provision and that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. If this provision does not apply to actions arising under the Securities Act or Exchange Act, please also ensure that the exclusive forum provision in the governing documents states this clearly, or tell us how you will inform investors in future filings that the provision does not apply to any actions arising under the Securities Act or Exchange Act. In addition, we note that, on page 65, you state that your amended and restated certificate of incorporation will provide for an exclusive forum in the Court of Chancery of the State of Delaware and in the U.S. federal district courts, and, on page 179, you identify only the Court of Chancery of the State of Delaware as the exclusive forum. Please revise for consistency.

RVMD answered

See the reply above.

Use of Proceeds, page 70
SEC asked (7)
Please revise to disclose an estimate of how far in the development of your multiple RAS programs the proceeds from this offering will allow you to reach. Also, please disclose the total estimated cost of each of the specified purposes for which the net proceeds are intended to be used, and, if material amounts of other funds are necessary to accomplish the specified purposes, provide an estimate of the amounts of
Rest of the question

such other funds and the sources thereof.

RVMD answered

See the reply above.

Capitalization, page 73
SEC asked (8)
Please revise to disclose the appropriate short-term nature of the marketable securities included in your capitalization table as of September 30, 2019, or remove as necessary. If material, also include disclosure of your accounting and policy for such securities in your pending unaudited interim financial statements as of September 30, 2019.
Rest of the question

Management’s discussion and analysis of financial condition and results of operations Critical accounting policies, significant judgments, and use of estimates Stock-based compensation, page 99

RVMD answered

See the reply above.

Capitalization, page 73
SEC asked (9)
Once you have an estimated offering price or range, please explain to us the reasons for any differences between the recent valuations of your common shares leading up to the initial public offer and the estimated offering price. This information will help facilitate our review of your accounting for equity issuances including stock compensation. Business
RVMD answered

See the reply above.

Our pipeline · Our SHP2 inhibitor, RMC-4630, page 111
SEC asked (10)
On page 111, please disclose the type of animal tested, the length of the test, the exact number of animals in each test, the dose the animals received in each test, and whether graphs (a) through (d) show the average or mean results. Similarly, please identify the animals tested in the studies described on pages 112 to 115. Also, please disclose the number of mice tested in Figure 7 on page 116.
Rest of the question

In addition, in your discussion of these studies and throughout the prospectus, please remove your assessments that the studies were effective or that your product candidates are or will be effective as only the FDA and foreign government equivalent regulators have the authority to determine whether the product candidate is effective or safe.

RVMD answered

See the reply above.

Our RAS(ON) portfolio · Our RAS (ON) inhibitor programs, page 120
SEC asked (11)
Please tell us how many times you tested the inhibitors in the studies described in Figures 13 to 20 on pages 122 to 127 and whether the graphs demonstrate the average or mean of the studies conducted. In addition, please revise to remove comparisons of your inhibitors to other inhibitors unless you have conducted a head-to-head clinical trial.
Rest of the question

In this regard, we note your comparison of RMC-5552 to other mTOR active site inhibitors on page 127. Also, in Figure 21, please disclose the number of mice tested and whether the results observed were statistically significant.

RVMD answered

See the reply above.

Collaboration agreement with Sanofi, page 128
SEC asked (12)
We note that you are responsible for 20% of the expenses associated with the identification, validation and optimization of SHP2 inhibitors for 2018-2020 pursuant to the research plan and budget under the collaboration agreement with Sanofi.
Rest of the question

Please provide quantitative information regarding these costs, and revise your prospectus summary and throughout to clarify that you are responsible for 20% of the costs associated with the identification, validation and optimization of SHP2 inhibitors for 2018 to 2020. In addition, please describe the material terms of the Quality Agreement and Clinical Supply Agreement with Sanofi or tell us why you believe this is not necessary. In this regard, we note your disclosure on page 171. Financial Statements Notes to Financial Statements 7. Acquisition of Warp Drive, page F-22

RVMD answered

See the reply above.

Collaboration agreement with Sanofi, page 128
SEC asked (13)
Provide us your consideration of whether disaggregating the $55.8 million in-process research and development asset by individual programs would provide useful information, if such information is available.
RVMD answered

See the reply above.

SEC letter of Nov 5, 2019 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
Prospectus Summary · Overview, page 1
SEC asked (1)
We note your revised disclosure on page 1 and throughout in response to comment 1 that RMC-4630 is a potent and selective inhibitor of SHP2, "based on preclinical evidence described in this prospectus." Please provide a summary of the preclinical studies in the prospectus summary, including the range of results observed, a description of how the test was conducted and the number of tests conducted.
Rest of the question

Similarly, on page 103, please revise to include a summary of the preclinical study conducted with RMC-4530, including the range of results observed, how the test was conducted and the number of tests conducted. Certain relationships and related party transactions

RVMD answered

No reply letter found.

Transactions with Sanofi, page 174
SEC asked (2)
Please include the disclosure required by Item 404 of Regulation S-K for the Quality Agreement and Clinical Supply Agreement with Sanofi, including the approximate dollar value of the amount involved with these agreements.
RVMD answered

No reply letter found.

Prospectus Summary · Our product candidates, page 3
SEC asked (1)
We note your disclosure on page 4 that you have entered into an agreement with Amgen to evaluate the combination of RMC-4630 and Amgen's KRASG12C (OFF) inhibitor AMG 510 in a Phase 1b trial that will be conducted by Amgen. Please describe the material terms of this agreement and file it as an exhibit to your registration statement.
Rest of the question

Management’s discussion and analysis of financial condition and results of operations Comparison of the Results of Operations for the nine months ended September 30, 2018 and 2019, page 95

RVMD answered
In response to the Staff’s comment, the Company respectfully advises the Staff that it does not believe that the agreement the Company entered into with Amgen to evaluate the combination of RMC-4630 and Amgen’s

KRASG12C (OFF) inhibitor AMG 510 in a Phase 1b trial (the “Amgen Agreement”) is a material contract under Item 601(b)(10) of Regulation

S-K.
Rest of the answer

Item 601(b)(10)(ii) of Regulation S-K states that “[I]f the contract is such as ordinarily accompanies the kind of business conducted by the registrant and its subsidiaries, it will be deemed to have been made in the ordinary course of business and need not be filed unless it falls within one or more of the following categories, in which case it shall be filed except where immaterial in amount or significance.”

Contracts Not Made Outside the Ordinary Course of Business

The Company advises the Staff that the Amgen Agreement was not entered into outside the ordinary course of business. As described in the Registration Statement, the Company is a clinical-stage biopharmaceutical company. The Company expects the research and development of its product candidates will require various studies and trials, some alone and some in combination with other products. As such, the Company regularly enters into various forms of agreements to test and develop its product candidates. For this reason, the Company respectfully submits that the Amgen Agreement was not entered into outside the ordinary course of its business.

The Company’s Business is Not Substantially Dependent on the Amgen Agreement

Subsection (B) of Item 601(b)(10)(ii) states that a contract entered into in the ordinary course of business would be a “material contract” if such contract is a “contract upon which the registrant’s business is substantially dependent, as in the case of continuing contracts to sell the major part of registrant’s products or services or to purchase the major part of registrant’s requirements of goods, services or raw materials or any franchise or license or other agreement to use a patent, formula, trade secret, process or trade name upon which registrant’s business depends to a material extent.”

The Company respectfully advises the Staff that the Company’s business is not substantially dependent on the Amgen Agreement. In particular, the Amgen Agreement is limited in scope to matters relating to the performance by Amgen of the Phase 1b trial to evaluate the combination of RMC-4630 and Amgen’s KRASG12C (OFF) inhibitor AMG 510 and the Amgen Agreement does not address economic rights relating to development or potential commercialization. In addition, the Company has another ongoing clinical trial and other planned clinical trials that are not in partnership with Amgen. As such, the Company is not substantially dependent on the Amgen Agreement. The Company respectfully submits that the Company and its business are not substantially dependent on the Amgen Agreement and that filing the Amgen Agreement as a material contract would not enable investors to form a more informed view of the Company’s business as a whole.

Read in the reply
Prospectus Summary · Our product candidates, page 3
SEC asked (2)
We note your 287%, 95% and 48% increases in collaboration revenue, research and development expense, and general and administrative expense during the nine months ended September 30, 2019 compared to the same period in 2018. Please expand each of these disclosures to explain whether you believe any of these increases represent a trend to continue in future periods.
Rest of the question

See Item 303(b) of Regulation S-K, including Instruction 3 thereto.

RVMD answered
In response to the Staff’s comment, the Company has revised page 96 of the Registration Statement.
Read in the reply
Management · Compensation committee interlocks and insider participation, page 178
SEC asked (3)
Please update to include disclosure regarding the last completed fiscal year. Exhibits and financial statement schedules, page II-3
RVMD answered
In response to the Staff’s comment, the Company has revised page 178 of the Registration Statement.
Read in the reply
Management · Compensation committee interlocks and insider participation, page 178
SEC asked (4)
Please file as exhibits to your registration statement the forms of the new employment agreements you intend to enter into with your named executive officers in connection with this offering.
RVMD answered
In response to the Staff’s comment, the Company has filed as exhibits 10.9, 10.10 and 10.11 the employment agreements entered into with the Company’s named executive officers in connection with this offering.

* * *

We hope the foregoing answers are responsive to your comments. Please do not hesitate to contact me by telephone at (650) 463-3043 or by email to [email protected] with any questions or comments regarding this correspondence.
Read in the reply
Report of Independent Registered Public Accounting Firm, page F-2
SEC asked
We note that your amended Form S-1 has been updated to reflect a 1-for-4.8661 reverse stock split of your common stock and redeemable convertible preferred stock to be consummated prior to the effectiveness of your planned initial public offering, which was approved by your Board of Directors on January 30, 2020.
Rest of the question

Please address the following: • Please ensure that your auditors provide reports that are fully compliant with Rule 2.02 of Regulation S-X, including the date of the accountants report. • Please ensure that your auditors provide consents that are fully compliant with Item 601 of Regulation S-K, including the date of their consent.

RVMD answered
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of Revolution Medicines, Inc. (the “Company”) for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 4:00 PM, Eastern Time, on

February 12, 2020, or as soon thereafter as practicable, or at such other time thereafter as the Company or its outside counsel, Latham & Watkins LLP, may request by telephone that such Registration Statement be declared effective.

Pursuant to
Rest of the answer

Rule 460 under the Act, we, as representatives of the several underwriters, wish to advise you that we have carried out the following distribution of the Company’s preliminary prospectus dated February 3, 2020:

(i)

Dates of distribution: February 3, 2020 through the date hereof

(ii)

Number of prospective underwriters to which the preliminary prospectus was furnished: 4

(iii)

Number of preliminary prospectuses furnished to investors: approximately 1,900

(iv)

Number of preliminary prospectuses distributed to others, including the Company, the Company’s counsel, independent accountants and underwriters’ counsel: approximately 240

The undersigned advise that they have complied and will continue to comply, and each underwriter has advised the undersigned that it has complied and will continue to comply, with the requirements of Rule 15c2-8 under the Securities Exchange

Act of 1934, as amended.

[Signature Page Follows]

Read in the reply

Also in this review: company letter, Feb 10, 2020, company letter, Feb 11, 2020, company letter, Jul 6, 2020, company letter, Jul 6, 2020

Letters without questions

Other letters

UPLOAD and CORRESP
6 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like
  • Sep 27, 2023 · RVMD: letter to the SEC · Registration Statement on Form S-4 · File No. 333-274499 · Request for Acceleration of...
  • Sep 20, 2023 · SEC: will not review the filing · Revolution Medicines, Inc. · Registration Statement on Form S-4 · Filed September 13,...
  • Feb 1, 2021 · RVMD: letter to the SEC · Revolution Medicines, Inc. · Registration Statement on Form S-1 (File No. 333-252613)...
  • Feb 1, 2021 · RVMD: letter to the SEC · Revolution Medicines, Inc. Registration Statement on Form S-1 · (Registration No. 333-252613)
  • Jan 25, 2021 · SEC: letter · Revolution Medicines, Inc. · Draft Registration Statement on Form S-1 · Submitted...
  • Jun 15, 2020 · SEC: letter · Revolution Medicines, Inc. · Draft Registration Statement on Form S-1 · Submitted June...

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 20 letters filed since 2019-10-16. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RVMD/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.